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ABSTRACT  
   
Objectives: To investigate the potential of vinegar supplementation as a means for 
reducing visceral fat in healthy overweight and obese adults, and to evaluate its effects on 
fasting blood glucose and fasting insulin.  
Subjects and Methods: Forty-five sedentary overweight and obese adult participants with 
a waist circumference greater than 32 inches for women and 37 inches for men were 
randomly assigned to one of two groups, the vinegar group (VIN, n=21) or the control 
group (CON, n=24), and instructed to consume either two tablespoons of liquid red wine 
vinegar (3.6g acetic acid) or a control pill (0.0225g acetic acid) twice daily at the 
beginning of a meal for 8 weeks. Participants were also instructed to maintain normal diet 
and physical activity levels. Anthropometric measures, dual-energy x-ray absorptiometry 
(DXA) scans, blood samples, and 24-hour dietary recalls were collected at baseline and at 
end of trial. A compliance calendar was provided for daily tracking of vinegar 
supplementation.  
Results: Compliance to vinegar supplementation averaged 92.7 ±13.3% among the VIN 
group and 89.1 ±18.9% among the CON group. There were no statistically significant 
differences in anthropometric measurements between baseline and week 8: weight 
(P=0.694), body mass index (P=0.879), and waist circumference (P=0.871). Similarly, 
DXA scan data did not show significant changes in visceral fat (P=0.339) or total fat 
(P=0.294) between baseline and week 8. The VIN group had significant reductions in 
fasting glucose (P=0.003), fasting insulin (P <0.001), and homeostatic model assessment 
of insulin resistance scores (P <0.001) after treatment.  
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Conclusions: These data do not support the findings from previous studies that indicated 
a link between vinegar supplementation and increased fat metabolism, specifically 
visceral fat reduction. 
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CHAPTER 1 
INTRODUCTION 
The marvels of vinegar have been endorsed throughout history.  Evidence of 
vinegar is speckled along the timeline of ancient civilizations.  Babylonians in 5000 BC 
made date vinegar to preserve food.  Urns containing remnants of vinegar were found in 
Egyptian tombs dating back to 3000 BC.  Romans in 1000 BC would dunk their bread in 
fruit vinegars.  Notably, it was in 400 BC in ancient Greece that Hippocrates, deemed the 
father of modern medicine, would realize its medicinal benefits by prescribing vinegar to 
treat various illnesses and wounds.1,2  
 The concept that food offers therapeutic benefits in the treatment, prevention and 
reduction of various diseases would become dubious as the study of pharmacology 
emerged.  However, in this precarious climate of decreased health status in Americans 
and escalating health care costs, the focus on natural and preventative health practices 
have taken strong emphasis within public health as obesity and obesity-related conditions 
became highly prevalent in recent decades.  
Obesity-related conditions in particular are of significant concern and pose a great 
deal of burden on the health care system.  Metabolic syndrome is strongly associated with 
obesity rates.3-5  This condition is diagnosed when three or more specific risk factors co-
exist, increasing risk of stroke, heart disease, and diabetes among others.  Those specific 
risk factors include a waist circumference >40 inches for men and >35 inches for women, 
high triglyceride levels, low levels of high density lipoproteins (HDL), high blood 
pressure and high fasting blood sugar.3-5 
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A large body of evidence shows that visceral fat, in particular, has a significantly 
negative impact on health.  Visceral fat is the abdominal fat that surrounds the internal 
organs and is difficult to lose.  On the other hand, subcutaneous fat that builds under the 
skin has less negative impact on overall health and is relatively easier to lose.  Health 
problems of particular concern include elevated levels of fasting blood glucose and 
triglycerides, insulin resistance, high blood pressure, and systemic inflammation.5  
Reduction in visceral fat would precede great benefits in overall health as improvements 
in fasting blood glucose levels, triglyceride levels, insulin sensitivity, blood pressure, and 
inflammation would be seen.3-5 
Vinegar consumption has been shown to improve health status as observed in 
multiple research studies.6-10  Of substantial relevance is the active ingredient in vinegar, 
acetic acid.  Findings from a rat model revealed a link between the metabolism of acetic 
acid and fat oxidation.6  Consumption of vinegar was shown to increase phosphorylation 
of the adenosine monophosphate-activated protein kinase enzyme, or AMPK, triggering 
lipolysis in adipose tissue, and fatty acid oxidation in the liver.  Despite being fed a high 
fat diet, increased vinegar consumption in rats resulted in elevated AMPK levels while 
body weight, fat, and triglycerides decreased.6 
There is a need for more human studies to identify the potential link between 
vinegar consumption and fat reduction as observed in several animal trials.6,11,12  A study 
that may potentially identify this relationship would provide an optimistic alternative for 
individuals struggling with associated health consequences or the increased risk of these 
health consequences.  
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Purpose of Study 
The purpose of this study was to identify a link between vinegar consumption and 
visceral fat reduction in healthy adults with abdominal obesity.  Participants ingested a 
liquid vinegar drink or a low-dose vinegar control pill two times per day, for an 8-week 
treatment period. 
Research Aim and Hypothesis 
H1 Daily red wine vinegar consumption will be associated with visceral fat reduction as 
measured by Dual-Energy X-Ray Absorptiometry (DXA) after 8 weeks compared to the 
control (low-dose vinegar pill) in a sample of healthy adults with abdominal obesity. 
H2 Daily red wine vinegar consumption will be associated with a decrease in waist 
circumference after 8 weeks compared to the control  (low-dose vinegar pill) in a sample 
of healthy adults with abdominal obesity. 
Definition of Terms  
• Acetic Acid – The active ingredient in vinegar. It is a weak acid and its chemical 
structure is CH3COOH.  
• Abdominal Obesity – Defined as a large amount of fat in the abdominal region 
of the body and is an independent risk factor for metabolic syndrome.  It is 
characterized by a waist circumference >40 inches for men and >35 inches for 
women. 
• Adipokine – Cell signaling proteins produced by adipose tissue that have a wide 
range of physiological functions including those to maintain energy homeostasis 
and promote inflammatory responses.  
  4 
• Adiponectin – An adipokine hormone that functions to help regulate fatty acid 
metabolism and glucose levels. 
• Body Mass Index (BMI) – An estimated measure of body fat based on weight 
relative to height.  The formula for BMI is [weight (kg) / height (m)2]. Adult 
weight status categories associated with BMI ranges are: 
Underweight: < 18.5 kg/m2  
Normal weight: 18.5 - 24.9 kg/m2  
Overweight: 25.0 - 29.9 kg/m2   
Obese: ≥ 30.0 kg/m2  
• Dual-Energy X-Ray Absorptiometry (DXA) – Used to assess bone density and 
body composition through x-ray technology. 
• Fatty Acids – Molecules that are a straight, long hydrocarbon chain that 
terminates with a carboxylic acid group (-COOH) and is a component of more 
complex lipids. They are classified by their chain length, degree of saturation, 
specific shape, and essentiality in humans.  
• Free Fatty Acids – A free fatty acid is a by-product of fat metabolism.  They are 
released from lipid molecules via lipolysis. 
• Leptin – Known as the “satiety hormone” because it signals the brain to inhibit 
hunger and promote feelings of fullness.  It is primarily produced by adipose cells 
to maintain energy balance. 
• Metabolic Syndrome – A specific group of risk factors that are known to 
increase stroke, diabetes, and heart disease risk.  Risk factors include abdominal 
obesity, elevated levels of triglycerides and fasting blood glucose, low HDL 
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cholesterol, and high blood pressure.  This condition is diagnosed when three or 
more of these risk factors co-exist, increasing risk of stroke, heart disease, and 
diabetes among others.  
• Obesity – A chronic condition defined by excessive amounts of adipose tissue 
and measured at or above a BMI of 30.0 kg/m2.  
• Visceral Fat – A specific type of fat located in the abdominal cavity of the body 
and surround the organs; also known as abdominal fat or central fat. 
Delimitations and Limitations 
Delimitations:  
• Recruitment for this study included healthy adults between 18-45 years of age, 
who are nonsmokers.  A minimum waist circumference for men > 37 inches, 
and waist circumference for women > 32 inches was required. All study 
participants were healthy, as defined as being free from disease.  Female 
participants could not be pregnant.  The results from this study may not apply 
to age groups or disease states outside these inclusion criteria.  
Limitations:  
• It was requested that participants maintain normal eating and exercise habits 
through the 8-week study period.  Adherence to this request, however, cannot 
be guaranteed. 
• Participants were given directions for consuming their drink supplements and 
encouraged to follow them.  Adherence to this request, however, cannot be 
guaranteed.  
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• Eight weeks may be too short a time span to see a significant change in 
visceral fat. 
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CHAPTER 2 
REVIEW OF THE LITERATURE 
Vinegar Sources and Production 
 In the simplest definition, vinegar is fermented alcohol.  It is the product of the 
double fermentation of any sugar or starch-containing substrate.13  Yeasts begin the 
production process as they feed on the natural sugars found in the carbohydrate source. 
As it feeds, known as fermentation, yeast breaks down the sugar into carbon dioxide and 
alcohol (ETOH).2,14  The acetic acid bacteria (common name), more formally known as 
Acetobactor aceti (A. aceti abbreviated), then converts the alcohol to acetic acid, hence it 
is double fermented.2,14  For optimal growth of acetic acid bacteria, the temperature range 
should be maintained at 77-86 degrees Fahrenheit, with a pH within the 5.0-6.5 range.1  
The sour taste and distinctive smell of vinegar emanates from its acetic acid content.2  
Acetic acid is considered a weak acid as it never completely dissociates in water, giving 
vinegar a very low pH value.  It is this low pH value that gives vinegar its antibacterial 
property.  The common commercial vinegar typically contains 4-7% acetic acid.  Vinegar 
with higher concentrations of acetic acid can be unsafe and a health hazard due to risk of 
skin burns upon contact, and coughing or nausea with inhalation.    
Several production methods are used to make vinegar.  Commercial production 
may utilize the traditional, yet slow, process for a higher quality product or speed up the 
process via submerged culture.15  The vinegar-making process requires the presence of 
oxygen, while the fermentation of grapes for wine-making or hops for beer-making 
requires its absence.  
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In traditional vinegar-making, a film covers the surface of the solution made up of 
yeast and acetic acid bacteria.  This is known as the mother of vinegar and it attracts 
vinegar eels.  These nematodes are a natural occurrence during the acetification process 
(conversion of alcohol to acetic acid) and, while harmless, they are filtered from the 
solution and the vinegar is pasteurized to prevent their reappearance.2,14  Some vinegar 
manufacturers promote the mother of vinegar with claims that there are health benefits 
associated with its consumption beyond that of the vinegar however, these claims have 
not been scientifically substantiated.  
The A. aceti bacteria require oxygen to convert alcohol into acetic acid, which is 
limited to surface exposure to the air in traditional production.  In order to speed up the 
process beyond traditional and naturally organic methods, more oxygen must be provided 
to the bacteria.  The submerged culture method for producing vinegar is characterized by 
supplying oxygen to the liquid solution during the fermentation process, resulting in an 
accelerated production of vinegar.14  The more oxygen that can be provided, the faster the 
production of the vinegar product.  To do this, air bubbles are generated into the solution, 
increasing the air-liquid surfaces, and thus increasing oxidation.14  However, an 
appreciable loss of quality is the consequence of the increase of oxygen flow in order to 
produce a product quickly and minimize manufacturing costs.  To give perspective, a 
traditional vinegar may take as long as a few months to ferment while industrial vinegar 
may be produced in as little as one day.1  
Another variation of vinegar production is an adaptation of the traditional method, 
known as the Orleans, or continuous, method.1,2  This vinegar production process allows 
for air to circulate through holes placed on the sides of the wooden barrels.  A funnel is 
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extended from the barrel base to pour additional liquid directly into the bottom of the 
barrel solution in order to prevent any alteration to the mother of vinegar sitting on the 
surface.  This method is generally accepted as high quality for its organoleptic 
complexity.1,13,14  
The ageing process contributes to the quality of the vinegar product because it 
takes time for the various elements in the vinegar-making process to permeate, ultimately 
creating a higher quality product.15  Elements influencing quality include the source of 
the vinegar and the complex metabolic and organic chemical reactions that occur during 
fermentation.  Additionally, the biological interactions between the wood materials of the 
barrels and the bacteria generate a complex network of compounds and aromas, and 
soften the distinct pungency of the overall product.1,13,14 
Various organic acids are produced by acetic acid bacteria during the sugar and 
alcohol oxidation process.  While acetic acid is most abundant, other bioactive substances 
include vitamins, mineral salts, and amino, polyphenolic, and metabolic acids.  Red wine 
vinegar in particular, contains acetic, citric, formic, lactic, malic, succinic and tartaric 
acids.1,2,14 
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Figure 1. Production of Vinegar Schematic Diagram 
 
Vinegar products sold in the United States must contain at least 4% acidic acid 
concentration to be classified as vinegar.  Common vinegar products will have 4-7% 
acetic acid concentrations and include red wine, apple cider, raspberry, balsamic, 
pomegranate, rice, and malt vinegar.2  In Europe, regional standards are placed on 
vinegar depending on origin of the vinegar, much like European standards for wine.  For 
example, traditional balsamic vinegar has two classifications (Aceto Balsamico 
Tradizionale di Modena DOP and Aceto Balsamico Tradizionale di Reggio Emilia DOP) 
and are regulated products exclusively produced in the Modena province or the greater 
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Emilia region of Italy and are protected under the Denominazione di Origine Protetta, 
which is translated Protected Designation of Origin (DOP).15  
Vinegar as a Functional Food 
 History 
 The history of vinegar dates back to ancient civilizations from all over the world. 
In 5000 BC, Babylonians added flavorings to date vinegar such as fruit and honey to 
season their food.2  They also discovered its use as a food preservative.  In 3000 BC, 
Egyptians stored vinegar in the tombs of their deceased to be used as gift offerings for 
their Gods.2  In 1000 BC, Romans used fruit vinegar as a flavorful condiment to dip their 
bread in.15  In 400 BC, the father of modern medicine, Hippocrates from ancient Greece, 
recognized the medicinal potential of vinegar and used it in treating a variety of 
ailments.15  
 Functional Properties 
Functional food, or nutraceuticals, are defined as a food providing health benefits 
beyond that of the basic nutritional needs.16  The therapeutic effects of vinegar are 
demonstrated in multiple studies.1  Of significance are those showing how vinegar effects 
the glycemic response, delays gastric emptying, and functions as an antimicrobial 
agent.2,16,17  The mechanisms that are responsible for the health benefits of vinegar are 
found to be the influence of the main ingredient in vinegar, acetic acid.18  As such, 
vinegar has been recognized as a nutraceutical due to its physiologically functional 
properties.  
Polyphenols are known to provide antioxidant benefits.  Regular consumption of 
flavonoids, the major source of polyphenols in the human diet, is associated with reduced 
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risk of various chronic diseases and cancers.19  Specifically, flavonoids provide 
protection against the oxidation of low density lipoproteins (LDLs), reducing oxidative 
stress and inflammation which, as will be discussed in further detail, may be a factor in 
the development of visceral fat and fatty liver.20  Fermented grape and grape juice 
products, including red wine and red wine vinegar, are excellent sources of 
polyphenols.1,20 
 Recent Popularity 
Vinegar has been increasing in popularity in recent years as a functional food, 
resulting from the strong emphasis on natural and preventative health practices within 
public health as the incidence of obesity continues to rise.  Lifestyle-related diseases are 
preventable chronic conditions caused by deleterious lifestyle factors.21  These conditions 
include cardiovascular disease, stroke, obesity, and diabetes, among other conditions 
linked to smoking, and alcohol and substance abuse.21  Because of its increasing 
prevalence and the increasing health care costs associated with these diseases, great 
interest in functional foods has spurred heavy research to combat existing conditions as 
well as provide scientific evidence to support preventative treatments.  
Recent reports in the research literature that vinegar can increase and prolong 
satiety and independently decrease fat have been touted by mass informational sources. 
The notion that vinegar is a functional food for chronic metabolic disorders as well as a 
potential weight loss aid popularized by the media and sparking interest all across the 
developed world has led to commercially marketed weight loss supplements containing 
vinegar.22  While there are studies showing an association between the reduction of fat 
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and vinegar consumption, the evidence supporting these claims, or the safety of vinegar 
consumption for that matter, are not sufficient at this time.4,11,22,23  
Acetic Acid 
Acetic acid is part of a family of organic compounds known as carboxylic acids 
and are identified by the -COOH carboxyl group.  The compound is distinguished by the 
addition of a methyl group (CH3).  It’s molecular formula is CH3COOH.15  Arguably the 
most important in the carboxylic acid family, acetic acid is the active ingredient in 
vinegar and is the responsible compound for the various health benefits associated with 
vinegar consumption.15  As previously illustrated, acetic acid is fermented by acetic acid 
bacteria from ethanol and derived from any carbohydrate source.2,13  Naturally produced 
vinegar is the product of a chemical reaction in which ethyl alcohol is partially oxidized 
producing acetaldehyde, and is then converted into acetic acid through an oxidation 
reaction.13,15  
Acetic acid is also produced as a byproduct of human metabolism.  After a fiber-
rich meal, gut bacteria found in the large intestine metabolize insoluble fiber and resistant 
starch through fermentation, breaking them down and producing short-chain fatty acids 
(SCFAs).18  Acetate (the oxidized form of acetic acid), propionate, and butyrate make up 
about 95% of SCFAs in the body, and they populate the colon and stool at a molar ratio 
of 60:20:20 respectively.24  The SCFAs that are produced in the gut can then be rapidly 
absorbed by colonic cells.18  Dietary acetic acid however is digested in the small 
intestines, along with most nutrients including glucose.18   
It is well documented that vinegar has a hypoglycemic effect however, the 
biological mechanism remains unclear.  The role of acetic acid in human metabolism 
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continues to be highlighted as the key constituent in vinegar.  Based on clinical 
observations, theories on how acetic acid may effect blood sugar levels include delayed 
gastric emptying, activation of gluconeogenesis, and the suppression of glucose 
facilitating enzymes in the epithelial cells of the small intestines.9,10,18,25 
AMPK 
 Origin and Function 
The evolution of AMPK provides an interesting perspective of its relationship to 
the insulin signaling pathway.  The enzyme is a heterotrimer made up of three subunits, a 
catalytic alpha and regulatory beta and gamma subunits.26  The genes that code for these 
three subunits are found in all eukaryotes including those single celled protozoa.26  They 
are more complex in humans as these distinct human genes code for multiple isoforms for 
each subunit, with at least 12 potential combinations.26  On the evolutionary timeline, the 
AMPK signaling pathway occurred well before the insulin signaling pathway.  Similar to 
the action of insulin, fluctuations in glucose levels (such as in starvation and fed states) 
are at least partially managed by the AMPK pathway.26  Further, the insulin signaling 
pathway is only found in multicellular animals.26  It has therefore become recognized that 
the AMPK signaling pathway is an important and highly conserved mechanism in the 
regulation of cellular energy. 
The role of AMPK is to detect a fuel deficiency in the cells of the body.  It acts as 
a master switch on certain metabolic pathways including lipogenesis, triglyceride 
synthesis, hepatic ketogenesis, and carbohydrate regulation in the blood.27  It regulates 
metabolism by facilitating the phosphorylation of key proteins that are necessary for the 
body to adapt to the present feeding conditions, specifically starvation or overfeeding, in 
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order to maintain energy balance.28  It may also have long term effects on the expression 
of genes involved in metabolic regulation.26  Recently, AMPK has been implicated for its 
central role in lipid metabolism.11  Because of the metabolic function of AMPK in the 
suppression of fatty acid synthesis and promotion of fatty acid oxidation, it is being 
explored as a promising new drug target in the treatment for obesity and glycemic control 
for diabetes. 
As energy becomes depleted in the mitochondria, body cells become stressed and 
adenosine monophosphate (AMP) levels increase.  This occurs with such conditions as 
hypoglycemia, hypoxia, or muscle contraction.26  As cellular energy production 
decreases, AMPK kick starts various pathways that breakdown other substrates to 
generate more adenosine triphosphate (ATP), the energy currency for body cells.26  
AMPK becomes activated and phosphorylated, functioning to regulate energy levels, 
while also protecting transmembrane transporters to maintain membrane 
potential.10,26,27,29 
AMPK and Insulin Resistance  
It is hypothesized that defects in the activation of AMPK, or a reduction of its 
activity (resulting from a sedentary lifestyle) exist in those with type 2 diabetes.27  
However, dietary as well as lifestyle changes such as incorporating acetic acid into the 
diet as well as increasing physical activity levels may improve sensitivity to the 
activation triggers of AMPK.10,26,27,29  Clinical treatment in the diabetes population 
include pharmaceuticals that mimic the biological processes to activate AMPK.29  Some 
medications that are commonly prescribed to mediate blood glucose, such as metformin, 
  16 
interrupts ATP production in the mitochondria and in doing so, these treatments activate 
AMPK by mimicking a starvation state at the cellular level.10,27,29 
It is important to note that the type and location of the adipose tissue is more 
indicative of insulin resistance risk than is body weight per se.  Key regulatory adipokine 
hormones, leptin and adiponectin, act synergistically to maintain energy balance.30  
Leptin inhibits hunger while adiponectin regulates glucose levels and fatty acid 
metabolism.  Together, they have been shown to promote insulin sensitivity and activate 
AMPK.27,30  Activation of this enzyme inhibits the synthesis of fatty acids, glycogen, and 
cholesterol, while stimulating glucose uptake and fatty acid catabolism.26,27  Further, 
adipose tissue in the abdominal area surrounding the organs (visceral adipose tissue) are 
known to possess increased hormonal activity.31  Higher levels of visceral fat are 
correlated with decreased levels of adiponectin.31  Adiponectin at low concentrations is 
associated with insulin resistance and type 2 diabetes, among other conditions such as 
cardiovascular disease and some cancers.29,31  
AMPK and Acetic Acid 
Acetic acid has been found to enhance the action of AMPK.  This suggests 
vinegar intake may reduce the accumulation of body fat and increase sensitivity to insulin 
by promoting AMPK activation.  Yamashita and colleagues11 explored the impact of 
acetate on lipogenic genes and obesity.  In this animal study, male rats with obesity-
related type 2 diabetes were split into two groups, an obese treatment group and an obese 
control group, while another group of rats served as the nondiabetic control.11  The obese 
treatment group received an oral administration of acetate at 5.2 mg/kg body weight, 
while the obese control received 5 mL/kg body weight of distilled water for 6 months.11  
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The results showed the obese treatment group had significantly lower triglycerides and 
cholesterol levels, and improved glucose tolerance compared to the obese control 
group.11  Northern blotting analysis for the obese treatment group showed a reduction in 
the gene transcription of several enzymes that play a role in lipogenesis in the liver 
however, there was no statistical significance in those enzymes playing a role in 
lipolysis.11  Further, western blotting analysis showed phosphorylated AMPK proteins in 
the liver was higher in the obese treatment group compared to that of the obese control 
group.11 
Therapeutic Effects of Vinegar 
Antiglycemic Properties of Vinegar 
Of special interest currently are the antiglycemic properties of vinegar.  Multiple 
studies have demonstrated reduced blood glucose levels after meals, as well as 
improvement to insulin sensitivity.  The literature continues to explore the underlaying 
mechanism however, the acetic acid in vinegar is credited for its glycemic lowering 
effects including the inhibition of glucose absorption and/or promoting cellular uptakes 
of glucose which consequently reduces glucose levels in the blood.18 
One of the first studies on the antiglycemic properties of vinegar was conducted 
in 1987 by Ebihara and Nakajima.  In their study, seven healthy participants were divided 
into two groups; a control group that ingested 300mL of a sucrose solution (53.6g 
sucrose) and an intervention group that ingested 300mL of sucrose and vinegar solution 
(50g sucrose with 60mL of strawberry vinegar containing 5% acetic acid).32  The area 
under the insulin response curve (insulin AUC) was 20% lower in the vinegar-ingesting 
group compared to the control group.32  In this same article, Ebihara and Nakajima also 
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observed the glucose response to a starch load in 12 rats divided into two groups.32  One 
group ingested the control meal containing a corn starch solution (100mg starch per 100g 
body weight) while the other ingested the test meal containing a corn starch solution plus 
2% acetic acid solution.32  Blood glucose levels were attenuated in the test meal group 
compared to the control.32 
A brief overview of carbohydrate digestion begins in the mouth with amylase, an 
enzyme in saliva.  Starch gets broken down into maltose and shorter polysaccharide 
chains.  Digestion continues with pancreatic amylase after passing the stomach as it 
enters the small intestine where polysaccharides are broken down further as they are 
hydrolyzed into disaccharides.18  Production of appropriate glycosidase enzymes 
(maltase, lactase, sucrase) are upregulated to further break down the disaccharides into 
monosaccharides.18  These single unit sugars are then available for absorption into the 
bloodstream through these monosaccharide-specific enzyme transport systems.18  While 
it is still unclear where in this process acetic acid may interfere with the postprandial 
glucose response, it is thought it may inhibit the absorption of glucose.  
In a study that aimed to explore the role of acetic acid in reducing postprandial 
blood glucose levels and its potential to inhibit the absorption of glucose, Ogawa and 
colleagues18 studied the glucose transport and disaccharidase activity in Caco-2 cells.  
This culture of cells was treated to mimic the epithelial cells of the small intestines for the 
purposes of examining its physiology.  In control cells without acetic acid, a glucose 
substrate was used to evaluate the glucose transport system.18  Sucrase enzyme activity 
increased as expected.18  Upon administration of acetic acid, disaccharidase enzyme 
activity and angiotensin-converting enzyme (ACE) activity levels were suppressed, 
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mitigating the postprandial sugar spike.18  The results of this study suggest that the 
mechanism that gives acetic acid its hypoglycemic properties are at least partially related 
to the suppression of disaccharidase activity.18 
One study, conducted by Brighenti and colleagues33, examined postprandial blood 
glucose in a more likely, real-life scenario.  The glucose response of five healthy subjects 
was measured over six test-meals which included salads dressed with olive oil only, olive 
oil with vinegar containing 1g acetic acid, or with olive oil and sodium acetate in the 
form of neutralized vinegar.33  White bread containing 50g of carbohydrates were added 
to three of the six test meals to induce a heavy carbohydrate load.33  Glucose and blood 
acetate were considerably lower after vinegar-dressed salads were consumed when 
compared to salad with olive oil only.33  While this study was limited due to the small 
sample size, it is important to note that in a highly likely scenario of a carbohydrate 
loaded meal, vinegar consumption, even in the small amount provided for salad dressing 
as demonstrated in this experiment, can have a significant effect in reducing the glycemic 
response.  
Johnston and colleagues34 explored the effect on postprandial glucose from the 
time of vinegar intake.  Twenty-nine fasting insulin sensitive and insulin resistant 
participants, and participants with type 2 diabetes were randomly assigned to drink a 
vinegar (40g water, 20g apple cider vinegar, and 1 teaspoon saccharine) or a placebo 
beverage.34  After two minutes, they ate a high carbohydrate meal (meal containing 87g 
total carbohydrates).34  Fasting, 30-minute postprandial, and 60-minute postprandial 
blood samples were collected.34  One week later, the test was repeated in a cross-over 
fashion.  In insulin resistant participants, the vinegar beverage taken two minutes before 
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the high carbohydrate meal improved insulin sensitivity at the 60-minute postprandial 
collection (P= 0.01), with improvements also seen in participants with type 2 diabetes 
(P= 0.07).34  Insulin sensitive participants who consumed the vinegar beverage 
experienced a significant reduction in postprandial insulin spikes.34  In another study led 
by Johnston and colleagues, a 20% reduction in postprandial glycemia was seen with as 
little as two teaspoons of vinegar when consumed with a complex carbohydrate-rich meal 
compared to a placebo treatment.35 
A recent systematic review and meta-analysis was conducted on clinical control 
trials reporting the effect of vinegar intake on the postprandial glucose response.25  
Across 11 clinical trials, 204 subjects were included with a range of 5-12 participants in 
each study.25  Participants’ disease states included healthy adults, individuals with type 1 
and 2 diabetes (type 1 diabetes involved in one study only), and those with insulin 
resistance and impaired glucose tolerance.25  Findings verified a statistical significance in 
the reduction of postprandial glucose and insulin responses as a result of vinegar 
consumption in healthy participants as well as those with a glucose disorder.25  It is 
noteworthy to point out that in a subgroup meta-analysis of participants with impaired 
glucose tolerance, insulin resistance, or diabetes, a stronger effect size in glucose AUC 
was observed.25 
Antiobesity Properties of Vinegar 
Vinegar as a functional food to help manage blood glucose and insulin sensitivity 
in those with pre-diabetes and type 2 diabetes may also help control body fat content.  
Several vinegar experiments and clinical trials have reported subsequent weight and fat 
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loss after vinegar treatment, as well as increased and prolonged satiety.4,9,10,22  However, 
the current scientific evidence on the effects of vinegar in reducing fat are weak. 
Findings from several studies have proposed mechanisms by which vinegar 
promotes antiobesity effects.1,4,18  Acetic acid, as the key component in vinegar, as well 
as acetate (conjugate base to acetic acid) are implicated in the activation of these 
proposed mechanisms.  These substrates have been shown to enhance the uptake of 
glucose and its utilization, and concurrently promote fat metabolism.8,11  
Ostman and colleagues evaluated the dose response effect of vinegar 
supplementation (white vinegar with 6% acetic acid; 18g, 23g, or 28g) on blood glucose 
and insulin, and satiety after 12 healthy participants consumed a bread meal containing 
50g of carbohydrates for breakfast.9  It was reported that as acetic acid content increased, 
satiety levels increased (linear relationship between satiety AUC and acetic acid content, 
(P= 0.004).9  Likewise, the vinegar supplementation prolonged satiety levels.  
Postprandial satiety increased greater than two-fold when participants consumed their 
bread meal with the highest dose of vinegar (28g) compared to that of the control meal 
containing only bread with no vinegar.9  This effect of vinegar on satiety may be an 
indirect mechanism for reducing body fat. 
Ok and colleagues6 used a rat model to examine how pomegranate vinegar (PV) 
consumption would affect adiposity in obese rats.  Fifty rats were equally split into five 
experimental diet groups: a high fat diet group (41.2% energy from fat), a low dose acetic 
acid group (high fat diet with 1.6% acetic acid per rat), a high dose acetic acid group 
(high fat diet with 3.2% acetic acid per rat), a low dose PV group (high fat diet with 
1.62% PV per rat), and a high dose PV group (high fat diet with 3.2% acetic acid per 
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rat).6  After 16 weeks, weight gain as a result of the high fat diet was suppressed in the 
high dose acetic acid and low dose PV rats.6  These same diet groups also experienced a 
decrease in white adipose tissue.6  Triglyceride levels declined in all dose acetic acid and 
vinegar groups while only low dose PV rats experienced a reduction in hepatic 
triglyceride levels compared to the control group.6  Investigators reported that the low 
dose PV group experienced about the same, or slightly better, results on body weight, 
plasma triglycerides, and hepatic utilization of fat than the high dose acetic acid group.6  
It was also noted that phytochemicals may be the reason for this property in vinegar 
compared to the acetic acid treatment alone.6  
Kondo and colleagues4 were among the first to study the impact of daily vinegar 
intake on body fat in humans.  In this randomized control trial, 155 obese (defined in 
Japan as BMI of 25-30 kg/m2) Japanese participants were placed into one of three test 
beverage groups: a placebo (n= 58; 500mL beverage containing 0mL apple vinegar/ 0mg 
AcOH/ 1250mg lactate), low dose (n= 59; 500mL beverage containing 15mL apple 
vinegar/ 750mg AcOH), or high dose (n= 58; 500mL beverage containing 30mL apple 
vinegar/ 1,500mg AcOH) group.4  Lactate was used to mimic the taste of vinegar in the 
placebo drink.  Beverages were consumed daily for 12 weeks by drinking half (250mL/ 
meal) after the breakfast meal and the rest after the dinner meal.4  Anthropometric 
measurements as well as blood samples and blood pressure were taken and recorded on 
weeks 0, 4, 8, and 12 of the treatment period, and week 16 (post-treatment).4  
Measurements from computed tomography (CT) scans were used to quantify total fat 
area (TFA), and visceral and subcutaneous fat areas (VFA, SFA), which were recorded at 
week 0 and week 12 of the treatment period.4  Diet and physical activity levels were 
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maintained over the 12 weeks with no significant differences between groups.4  
Significant reductions in body weight, BMI, and body fat ratio (BFR) were seen as early 
as week 4 in the low dose and high dose groups, and reductions were dose dependent in 
that reductions in the high dose group was greater than that of the low dose group.4  VFA 
and TFA decreased significantly in both vinegar-consuming groups.4  Further, 
triglyceride levels had a significant decrease in the low dose group at the fourth, eighth, 
and twelfth weeks, and a significant decrease in total cholesterol was seen at the twelfth 
week.4   
Darzi and colleagues22 were the first to investigate the palatability and tolerability 
of vinegar on appetite control and food intake using validated appetite-related visual 
analogue scale (VAS) questionnaires to assess appetite and nausea.  Palatability is the 
pleasure experienced by the food and beverages an individual consumes, and thus they 
are satisfying to the palate and enjoyable to the individual.  Appetite is controlled by both 
extrinsic and intrinsic factors that trigger food palatability, and signal satiety (the physical 
feeling of fullness) and satiation (the hormonally-driven response to stop eating) cues.36  
The tolerability of a food is the ability to consume and digest a food without side effects 
such as nausea.  Two related randomized crossover studies were conducted on healthy 
adults.22  The first examined the postprandial effects of vinegar consumption when the 
palatability of the vinegar had been altered but the acetic acid content remained the 
same.22  A breakfast meal (jam sandwiches; 8g olive oil spread, 16g strawberry jam, and 
two 38g slices of bread) was provided with one of the following vinegar beverages (white 
wine vinegar, 6% acetic acid): unpalatable (first drink: 25g vinegar, 25g sugar-free 
squash, 100g water; second drink: 50g sugar-free squash, 100g water), palatable (divided 
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into two drinks: 25g vinegar, 75g sugar-free squash, 250g water), or control beverage 
(divided into two drinks: 75g sugar-free squash, 275g water).22  The second study 
examined the effects of the orosensory stimulation of vinegar, sans acetate, on appetite 
and glycemic response by employing the modified sham feeding (MSF) technique.22  A 
milkshake (21g PRO, 60g CHO, 12.6g FAT) was consumed with a subsequent MSF 
phase that included a vinegar (30g white wine vinegar, 6% acetic acid with 150g water) 
or a control (180g water) beverage which was equally divided into 10 cups.22  The 
participants were instructed to drink and hold the beverage from one cup in their mouths 
for 25 seconds before expectoration, then to repeat with the next cup.22  An ad libitum 
meal was provided after 180 minutes for both studies.  VAS results from the first study 
found significant differences between the palatability of all beverages, with the 
unpalatable drink rated as least pleasant, the palatable drink rated more pleasant, and 
finally the control non-vinegar drink rated as the most pleasant to taste.22  A dose 
dependent relationship was shown between increased vinegar content and nausea.22  
Feelings of nausea significantly increased after consuming both vinegar drinks (palatable, 
unpalatable) compared to the control.  The unpalatable beverage induced greater feelings 
of nausea compared to the palatable beverage however, this increase was insignificant.  
Coinciding with nausea ratings was increased satiety, reduced hunger, and an influence 
on prospective food intake.  Ad libitum energy intake 3-hours and 24-hours post 
treatment was significantly lower in the vinegar beverage groups (mean energy intake in 
order from least to most: unpalatable, palatable, control).  As would be expected, VAS 
results on appetite showed that energy intake significantly increased in participants who 
rated the taste of their drink more pleasant and their breakfast more palatable.22  In the 
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second (orosensory) study, VAS survey results showed the vinegar beverage (held in 
mouth then expectorated) to be significantly less pleasant than the control beverage 
however, there were no differences in feelings of nausea between the vinegar and control 
treatments.22  Additionally, post-treatment appetite assessment showed no difference 
between beverages.22  Ultimately, consumption of vinegar had a significant influence on 
decreasing appetite22, supporting findings from other studies that have noted this effect.  
Orosensory stimulation (without ingestion) from a vinegar-containing beverage, as 
investigated in the second study, had no effect on appetite.  Symptoms of nausea 
significantly increased as the vinegar content in the beverage increased (and thus 
palatability decreased), indicating poor tolerance to vinegar ingestion but not to the 
pungent effects of vinegar on the senses.  Based on these findings, investigators reported 
that nausea following the ingestion of vinegar may be the underlying cause of what 
appears to be the effect vinegar has to decrease appetite, and increase satiety resulting in 
an overall reduction in subsequent energy intake.22 
Risks of Consumption  
Very few acute incidences have been documented related to the consumption of 
vinegar and, of those, they present as isolated cases.37,38  No other cases with similar 
acute adverse reactions have been reported.  
Dental Erosion 
Dental erosion, the permanent loss of dental hard tissue caused by chronic 
chemical (not bacterial) exposure, has had an increase in prevalence due to the increased 
intake of dietary acids.39,40  A growing body of evidence indicates that consuming acidic 
drinks such as in soft drinks, fruit juices, teas, alcoholic drinks, as well as some acidic 
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foods such as yogurts and fruits can cause erosion to the teeth.39  Vinegar, which can be 
found in salad dressings, marinades, alcoholic cocktails, and currently trending fermented 
drinks, is among these highly erosive agents.  This is exacerbated by the increased 
popularity of vinegar as a functional food and weight loss product in recent years.  
An in vitro study tested the erosive potential of 60 agents consisting of dietary 
substances and medications for changes in the hardness of tooth enamel with an initial 
two minute exposure and a subsequent two minute exposure.39  The chemical properties 
of these agents were characterized by pH value, titratable acidity, buffering capacity as 
well as its Ca, Pi, and F concentrations.39  A significant reduction in the surface hardness 
of the enamel specimens of extracted teeth was found in all but coffee, teas, unflavored 
mineral waters, some alcoholic drinks, medications, and yogurt.39  It was shown that the 
agents that had the highest potential of erosion were those with the lowest pH.39  With a 
very low pH level that can range from 2.0 to 3.5 depending on dilution and acetic acid 
concentration, consumption of vinegar has been implicated in contributing to dental 
erosion.39 
Another in vitro study used human enamel samples to test the erosion potential of 
30 different vinegar varieties.  The enamel samples were incubated in a vinegar liquid for 
4 or 8 hours.41  Mineral loss was demonstrated, with the highest mineral losses to the 
enamel sample incubated in the bio vinegar (pH of 3.1) and raspberry vinegar (pH of 
2.7).41 
Finally, a pilot in vivo human study examining resting saliva pH and vinegar 
ingestion, was conducted during an 8-week double-blind clinical trial (unpublished).42 
Investigators studied the daily intake of red wine vinegar and its effect on resting, 
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unstimulated salivary pH as well as dental erosion risk.42  Participants were randomly 
assigned to a vinegar treatment group or a control group.42  The vinegar group consumed 
a liquid vinegar drink containing two tablespoons of vinegar with 8-ounces of water two 
times per day just before a meal.42  Using a smart phone application, resting salivary pH 
was measured for seven days at baseline and for the final seven days (week 8) of the 
treatment period.42  Erosion was measured by a registered dental hygienist using the 
Basic Erosive Wear Examination (BEWE) protocol.42  No significance was found on 
saliva pH (P=0.499) after 8 weeks of vinegar treatment.42  However, changes in BEWE 
mean scores between the vinegar and control groups after 8 weeks was found to be 
significant (P= 0.051).42  
Obesity Epidemic 
Obesity is characterized as the excessive accumulation of adipose tissue in the 
body and identified when actual body weight is more than or equal to 20% above the 
ideal body weight for height and measured using the body mass index (BMI).  Gynoid 
and android obesity are two phenotypes of interest in current research, and they are 
classified based on the distribution of fat in the body.  Accumulation of excess fat in the 
abdominal area is known as android obesity, while gynoid obesity is the accumulation of 
excess fat in the lower trunk (hip and thighs) of the body.21  Much of the research on 
obesity in recent decades have sought to distinguish between these two obesity 
phenotypes in relation to metabolic health.  It has been found that increased visceral fat 
significantly increases risk of metabolic disorders as well as cardiovascular 
conditions.21,31,43 
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It is thought that obesity is the result of the metabolic inability to fully oxidize the 
fat consumed in the typical diet.  Excess fat accumulation occurs when fat intake 
chronically exceeds fat oxidation, which ultimately results in obesity.44  Studies have 
found that the utilization of fat in the body is limited compared to the utilization of 
carbohydrates and proteins.44,45  Flatt and colleagues45 investigated how the addition of 
fat to a typical meal with mixed macronutrient content would effect substrate oxidation.  
The addition of dietary fat above the standard intake of a mixed diet was shown to have 
no effect on either fat nor carbohydrate oxidation.45  This is undesirable because if 
increased fat intake does not increase fat oxidation, then it will be stored in adipose tissue 
adding to the total fat content in the body. 
Acheson and colleagues46 studied the impact of a high carbohydrate meal on 
macronutrient utilization.  They found that a meal high in carbohydrates hampered the 
oxidation rate of fat, and there was no indication that the excess carbohydrates were 
converted and stored in adipose tissue.46  In addition, glycogen stores increased up to 
33% above the maximum amount of total glycogen reserves that was previously believed 
the body can hold in storage.46  It was determined that carbohydrate oxidation adjusted 
(increasing in rate) to the excess carbohydrates consumed, after glycogen stores reached 
their maximum.46  This supports previous findings concluding that excess intake of 
carbohydrates leads to the upregulation of its oxidation; and in contrast, excess dietary fat 
does not increase its own substrate oxidation but rather, it is downregulated leading to 
increased storage of fat.45  Ultimately during periods of overfeeding, substrate oxidation 
will adjust to reach a balance between carbohydrate intake and utilization for energy, and 
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when the energy needs of the body have been met and glycogen stores have reached full 
capacity, all dietary fat consumed will be stored.45,46   
A similar investigation was conducted by Horton and colleagues, who also 
examined the difference in fuel utilization but extended the period of overfeeding to 14 
days.47  Sixteen lean and obese participants consumed excess energy 50% above baseline 
intake amounts during two separate overfeeding phases; an all-carbohydrate overfeeding 
phase and an all-fat overfeeding phase.47  Energy expenditure and substrate oxidation 
were measured using whole room indirect calorimeter, a gold standard for assessing fuel 
utilization.47  It was demonstrated that fat overfeeding did not promote any significant 
changes in fat oxidation or total energy expenditure (TEE) however, the oxidation of 
carbohydrates and TEE increased almost two-fold with the 14-day carbohydrate 
overfeeding period.47  They found that fat overfeeding led to the storage of 90-95% of the 
excess dietary fat over the 14-day trial period.47  The investigators noted that the positive 
fat balance was the result of the coordinated effect of decreased fat oxidation following 
an increase to carbohydrate oxidation.47  These findings are consistent with other 
overfeeding studies that examine fuel utilization and storage.  It is important to determine 
dietary strategies to stimulate fat oxidation in an effort to control body weight and reduce 
the risk of obesity. 
Metabolic Syndrome 
Metabolic syndrome, diagnosed when three or more specific risk factors co-exist, 
increases risk of stroke, heart disease and diabetes among others.3,4  Risk factors include a 
large waist circumference, high triglyceride levels, low HDL levels, high blood pressure, 
and high fasting blood sugar levels.  Substantial evidence is showing that increased levels 
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of visceral fat, characterized by waist circumferences greater than 40 inches for men and 
greater than 35 inches for women, is an independent risk factor for metabolic syndrome 
and may lead to a significantly negative impact on health.3-5  Therefore, a reduction in 
visceral fat would precede great benefits in overall health as improvements in fasting 
blood glucose levels, triglyceride levels, insulin sensitivity, blood pressure, and 
inflammation would be seen.3-5 
Visceral Fat 
Visceral fat is characterized by adipose tissue that accumulates in the abdominal 
area and surrounds the vital organs.  Subcutaneous fat, on the other hand, may be 
distributed anywhere underneath the skin.  The distinct differences between visceral and 
subcutaneous fat depots elucidate their metabolic contributions and disturbances.48  As 
the body ages, visceral fat accumulation tends to increase.49  Additionally, this adipose 
phenotype may be responsible for disturbing the normal metabolic processes in the body.   
Health Complications of Visceral Fat 
Visceral adiposity is an independent risk factor of metabolic syndrome and 
elevated levels increase the risk of metabolic disturbances.31  Other associated risks 
include cardiovascular and neoplastic diseases, as well as respiratory and inflammatory 
issues.31   
Venous blood drainage from subcutaneous adipocytes is transported into systemic 
circulation, while drainage from visceral adipocytes migrate to the liver via portal vein.49  
It is theorized that free fatty acids (FFAs) and adipokines released by visceral adipose 
tissue are transported into portal circulation directly to hepatocytes and potentially other 
downstream organs.  This would ultimately lead to an accumulation of fat in liver tissue 
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and trigger inflammatory responses causing short term as well as long term 
complications.49-51 
Korenblat and colleagues found a direct association between intrahepatic 
triglyceride (IHTG) content and impaired insulin function in the liver and skeletal 
muscle, as well as total fat content.52  Nielsen and colleagues used isotope dilution via 
catheter to the hepatic vein in 44 obese men and women and 24 lean men and women.53  
They determined that hepatic fat content is largely originated from intra-abdominal fat 
cells.53  A 20% greater concentration of plasma FFAs were seen in the obese group.53  
Further, the FFAs from visceral lipolysis that are transported to hepatocytes accounted 
for up to 50% of the liver fat.53  As visceral fat increased among the obese group, the 
hepatic FFA content increased as well (P=0.002 in obese men and women).53 
Inflammation and Visceral Fat 
Chronic inflammation and oxidative stress in the body are side effects of obesity. 
This obesity-related condition has been implicated as an important link to insulin 
resistance and cardiovascular disease.54  The Framingham Heart Study investigated 
circulating inflammatory markers to assess whether visceral fat has a stronger association 
to inflammation than subcutaneous fat.54  While both fat depots were found to have 
similar associations with elevated inflammatory markers, only visceral adipose tissue 
(VAT) was associated with multiple elevated markers of inflammation after adjusting for 
typical clinical measures associated with obesity.54 
An adipocyte is hypertrophic when it is expanded and reaches its maximum lipid 
storage capacity, and new subcutaneous adipocytes are recruited when excess lipids 
necessitate storage.55  When this mechanism of recruiting new adipocytes is impaired, 
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chronic hypertrophy of adipocytes can promote lipolysis and cell death in adipose 
tissue.55  Macrophage infiltration of adipose tissue occurs as an inflammatory response to 
remove the dying or dead cells.55  This inflammatory response has also been implicated 
in the renin-angiotensin system (RAS) dysfunction which results in hypertension (another 
risk factor for metabolic syndrome).56  Hypertrophic adipose cells are more resistant to 
insulin action and ultimately lead to the accumulation of ectopic fat in the visceral 
organs, liver, and muscle.51,55 
Insulin Resistance 
Peroxisome proliferator-activated receptor (PPARy) functions as an activator of a 
gene network involved in the regulation of adipose cell differentiation, lipid storage and 
metabolism, as well as insulin sensitivity throughout the body.55  Impairment of PPARy 
caused by gene mutation increases risk of insulin resistance and type 2 diabetes.55  
Another inflammatory consequence of hypertrophic obesity is retinol-binding protein 4 
(RBP4).43  It is correlated with visceral adipose tissue and its secretion is triggered when 
glucose uptake is impaired.55 
Fatty Liver 
Non-alcoholic hepatic steatosis (NAFLD) is a fatty liver disease that results from 
causes not related to excessive alcohol consumption and it is highly prevalent in the 
obese and in individuals with type 2 diabetes.57  There is a strong and direct correlation 
between visceral fat and intrahepatic fat.55  It can be argued that visceral fat, an important 
risk factor in metabolic syndrome, may be a secondary condition to the more indicative 
risk factor of intrahepatic fat.50,55  Fabbrini and colleagues50 aimed to distinguish 
intrahepatic triglyceride (IHTG) content as a primary marker of metabolic disorders and 
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not VAT.  It was noted that the link between increased VAT and metabolic disorders is 
primarily due to the correlation between VAT and IHTG, and increased IHTG should be 
recognized as an independent marker for obesity-related metabolic diseases.50 
Measurement Methods 
Lee and Gallagher (2008) conducted a review of assessment methods commonly 
used in determining human body composition, including visceral fat measuerments.58  It 
was noted that there is no error-free method or one that can provide an accurate measure 
of all body areas.58  Among the methods reviewed that assess visceral fat levels, the dual 
X-ray absorptiometry (DXA) was found to be a generally noninvasive and safe method 
with good accuracy and reproducibility that is acceptable for any age range.58  Other 
commonly used methods for measuring body composition, including bioelectrical 
impedance analysis (BIA), ultrasound, and computed tomography (CT) scans are not as 
safe, or produce poor accuracy estimations.58 
BIA measures the resistance of an electrical current that passes through the body’s 
water stores and estimates fat mass versus fat free mass as well as body weight.58  The 
benefits to this method include its ease of use, safety, and affordability compared to other 
methods.58  BIA may be inaccurate in the elderly due to the natural loss of total body 
water that occurs with age, and may overestimate fat free mass in the obese population or 
underestimate fat free mass in normal weight populations.58 
Computed tomography (CT) scans measures visceral fat through its cross-
sectional imaging capability.  A CT scan can create cross sectional sliced images of the 
body organs and tissues from rotating x-ray beams.  CT scanning is currently the gold 
standard for high accuracy in assessing adiposity, including visceral fat mass.  However, 
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this method is not without risks.  These scanners emit ionizing radiation which is known 
to break chemical bonds in bodily tissues, damage DNA by freeing charged ions, and 
increase risk of cancer.59   
Measuring waist conference is an easy, convenient, and low-cost screening tool 
that can provide an accurate estimate for assessing visceral fat.60  The World Health 
Organization (WHO) has determined that increased risk of comorbidities associated with 
obesity for the Caucasian population is indicated at a waist circumference of 38 inches or 
more (>94 cm) for men and 32 inches or more (>80 cm) for women.61  Gradmark and 
colleagues60 tested the validity of DXA, ultra sound, and anthropometry for assessing 
visceral fat compared to CT scanning, the gold standard method.  Anthropometric 
measures included BMI and waist circumference.60  The results from the DXA 
measurements were comparable to or less strongly correlated with CT measurements of 
adiposity in all comparisons in relation to waist circumference or BMI.60   
Based on the data from the third National Health and Nutrition Examination 
Survey (NHANES III) conducted by the National Center for Health Statistics, Zhu and 
colleagues concluded that lowering the threshold for waist circumference as an indicator 
of obesity-related health risks in the Caucasian male population to 35 inches and keeping 
with the WHO cut off of 32 inches for women may provide better health outcomes.62  
Berber and colleagues found that the optimal waist circumference cut offs were about the 
same in the Mexican populations.63  They also noted that their findings were similar to 
the established thresholds recommended for the Asian populations. 
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CHAPTER 3 
METHODS 
Participants and Study Design 
This study was a 2-arm parallel group, randomized, controlled trial.  The 
treatment period was 8 weeks, with one initial pre-screening visit before the start of the 
trial.  Participants met the following criteria: healthy man or woman between the ages of 
18-45, sedentary as defined by exercising < 3 times/week, not taking insulin or 
medications that may have affected their weight, and were willing to adhere to the study 
protocol of maintaining dietary intakes and consuming a vinegar drink or pill.  The waist 
circumference requirement for female participants was >32 inches and for male 
participants was >37 inches.  Individuals were excluded if they were pregnant or trying to 
get pregnant; had recently undergone any surgery to the abdomen or had a condition that 
may cause distention or swelling in the abdomen, such as pancreatitis, 
diverticulitis/diverticulosis, Crohn’s disease, irritable bowel syndrome, or ascites; and/or 
were taking medications, such as digoxin or diuretics, which can affect body weight.  
Data are reported for participants who completed the 8-week study (n=45).  All 
participants provided written consent.  This study was approved by the Arizona State 
University Institutional Review Board (IRB). 
Study Variables  
Acetic acid consumption was the independent variable in this study.  The 
participants in the VIN group were given instructions to drink the total of four 
tablespoons of vinegar each day (which provided a total of 3.6g acetic acid), mixed with 
water.  An 8-week supply of the red wine vinegar was pre-packaged in their original 
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manufactured bottles (Mantova Red Wine Vinegar, Mantova, Broccostella, Italy) and 
provided to the VIN group participants at the beginning of the trial.  While vinegar has 
many sources, red wine vinegar was specifically chosen because of its palatability, 
affordability, and common grocery store accessibility compared to other vinegar options. 
A limitation to this supplement may be the taste however, mixing with water (as 
instructed to study participants) helps dull the sour flavor.  For those participants in the 
CON group, they were given one bottle of vinegar pills (Apple Cider Vinegar Tablets, 
NowFoods, Bloomingdale, IL).  Instructions were given to swallow two whole pills each 
day (which provided a total of 0.0225mg acetic acid).  The visceral fat mass was the main 
dependent variable in this study.  It was hypothesized that participants in the VIN group 
would experience a greater loss of visceral fat and greater reduction in waist 
circumference in comparison to participants in the CON group.   
Protocol Procedures 
Data collection occurred at the start and upon completion of the trial period.  
Three visits were required of the participants; before the trial began, at the beginning of 
the trial period (week 1 of intervention), and lastly after completion of the trial.  Upon the 
first visit (before the intervention period) a consent form was signed by all candidates 
before continuing with pre-screening protocols to determine qualification per study 
criteria.  Pre-screening protocols of anthropometric measurements included height, 
weight, and waist circumference.  Subjects were stratified by gender, age, and weight, 
then randomly placed into two groups, an intervention group who were instructed to 
drink red wine vinegar (VIN), and a control group who were instructed to consume 
vinegar pills (CON).  
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Upon the second visit, participants were instructed to fast for 8 hours prior to their 
visit, with the exception of water.  Height, weight, and waist circumference were re-
measured.  A certified phlebotomist performed blood draws to test levels of fasting blood 
glucose and insulin.  Assessment of body fat was measured using the standard protocol of 
anthropometric measurements as well as from DXA scan data.  A certified radiologic 
technician performed the DXA scans.  Participants also completed a medical history 
questionnaire as well as the first of two 24-hour dietary recalls.  The second dietary recall 
form was to be filled out upon completion of the trial, which would then be used to 
confirm dietary maintenance throughout the trial.  VIN group participants received an 8-
week supply of red wine vinegar, and the CON group subjects received an 8-week supply 
of vinegar pills.  Participants received instructions for proper consumption of their 
vinegar supplement, and adherence to the assigned supplement for the full 8-week period 
was emphasized.  A compliance calendar was also provided to the participants to check 
mark each time they consumed their respective vinegar supplements.  This meant that 
100% compliance would have two check marks per day for 8 weeks. 
Participants in the VIN group were directed to mix two tablespoons of the 
provided red wine vinegar with 8 ounces of water before a meal, two times per day for 
the entire 8-week trial period.  CON group participants were directed to take one of the 
provided vinegar pills before a meal, twice daily for the entire 8-week trial period.  All 
participants were asked to continue current dietary and exercise behaviors throughout the 
study.  To ensure eating habits did not change, a 24-hour diet recall form was completed 
at baseline, as well as upon completion of the trial (third visit).  Again, anthropometric 
measurements including height, weight, and waist circumference as well as DXA and 
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blood draws per protocol were taken upon completion of the 8-week intervention period 
(third visit).  The compliance calendar was turned in to ensure adherence to the protocol.  
Participants also completed an exit survey to collect subjective data, such as any physical 
or symptomatic issues experienced with vinegar consumption as well as overall opinions 
on how the study was conducted.  Gifts cards valued at ten dollars were offered as 
compensation upon completion of the 8-week trial period (third visit). 
Laboratory Analyses  
Participants arrived at the test laboratory after an 8-hour fast and had their 
bloodwork taken via venipuncture by a certified phlebotomist.  Ten milliliters of blood 
was drawn (2mL via gray top vacutainer tube, 8.5mL via red top serum vacutainer tube).  
Blood drawing protocols via Standard Blood Specimen Collection by Venipuncture for 
Study Protocols and Procedures was used (Arizona State University, 2010).  Assessment 
of fasting insulin levels were measured using a radioimmunoassay (Human Insulin-
Specific RIA) kit.  Assessment of fasting blood glucose levels were measured using a 
Cobas analyzer (Cobas c111 Analyzer, Cobas, Indianapolis, IN).  Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR) scores were estimated using the standard 
HOMA calculation to estimate insulin sensitivity:  
fasting glucose (mmol/L) x fasting insulin (µU/L) 
22.5 
Each participant had a DXA (Lunar iDXA, General Electric, Fairfield, CT) scan 
performed by a certified radiologic technician for assessing total body fat and distribution 
including visceral fat mass.  Female participants provided a urine sample (at least 2 
ounces) to confirm absence of pregnancy (Medline Urinalysis Reagent Strips, Medline, 
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Mundelein, IL) due to the potential risk of fetal harm from exposure to minimal amounts 
of radiation from DXA scanning.   
Statistical Analyses 
Data are reported as mean values ± standard deviation.  Shapiro-Wilk and 
independent t-tests were used to test normality of the data.  Data were not normally 
distributed, and the Mann-Whitney nonparametric test was used to compare means 
between the experimental and control groups at baseline.  One way (ANOVA), univariate 
(ANCOVA), and multivariate (MANCOVA) general linear models (GLM) for repeated 
measures were used to determine significant treatment effects.  Chi square statistic was 
used to assess exit survey responses between groups and Cramer’s V for effect size.  A P-
value of <0.05 was considered significant.  The Statistical Package for Social Sciences 
(SPSS) software (SPSS Incorporated, Chicago, IL, USA) version 23 was used to 
complete the statistical analyses of the data.   
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CHAPTER 4 
RESULTS 
Recruitment of study participants occurred in two rounds.  In total for both 
recruitment periods, 297 respondents completed the survey.  Based on their responses, 62 
did not meet the qualifications of the study.  The remaining 235 respondents were 
emailed to schedule a pre-screen visit and 103 respondents made it to their scheduled pre-
screen visit.  The first pre-screening visit allowed investigators to verify survey responses 
after obtaining a written consent.  Forty eight were excluded after the first pre-screening 
visit: 37 were excluded because they did not meet the minimum requirement for the waist 
circumference measurement; three were not willing to maintain their current diet and 
exercise levels for the following 8 weeks; one did not meet the age range requirement; 
one was anemic; one had kidney disease; one had a gastric band; one was a smoker; one 
was excluded due to dietary restrictions; one had transportation and scheduling conflicts; 
and one was already taking vinegar supplements.  After pre-screening, 64 participants 
were eligible to continue the 8-week trial.  
Participants were paired by age, gender, and BMI.  They were then assigned to 
one of two groups by coin flip: the treatment group (VIN; n=32) or control group (CON; 
n=32).  Participants tracked their daily intake of liquid vinegar (VIN group) or vinegar 
pills (CON group) on a compliance calendar.  The trial and data collection began from 
their second visit.  Of 64 participants who proceeded to start the trial, 45 completed the 8-
week trial (VIN, n=21; CON, n=24).  Nine participants dropped as a result of attrition, 
four due to health issues unrelated to this trial, three due to work conflicts, two due to an 
adverse reaction to the liquid vinegar, and one due to pregnancy.  One participant could 
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not provide a blood sample due to difficulties obtaining the sample and another refused, 
which explains the smaller sample size in the blood data analysis.  Four men and 41 
women completed the entire 8-week trial. 
Initial participant screening included age, height, weight, BMI, and waist 
circumference using standard protocols to collect these data.  Using Mann-Whitney 
nonparametric tests, there were no significant differences in age (P=0.882), weight 
(P=0.335), BMI (P=0.851), or waist circumference (P=0.906) between the VIN and CON 
groups at baseline (Table 1).  One participant from the CON group was a multivariate 
outlier (specifically BMI, weight, and waist), as they were three standard deviations away 
from the mean.  Baseline data from this participant was excluded from baseline analysis. 
Height was significantly higher in the CON group (P=0.033; Table 1) with a mean height 
of 167.9 ±7.4 cm compared to the mean height among VIN group participants of 163.3 
±7.0 cm.  The age range of all participants was between 18-45 years.  For the VIN group, 
the mean weight was 74.3 ±11.5 kg and mean BMI 27.8 ±4.0 kg/m2.  The CON group 
had a mean weight of 80.7 ±16.9 kg and mean BMI of 28.5 ±4.9 kg/m2.  Mean waist 
circumference was 36.5 ±3.3 inches among the VIN group compared to 36.9 ±4.0 inches 
among the CON group.  Ingestion of liquid vinegar (VIN group) or vinegar pills (CON 
group) was tracked using a compliance calendar.  The mean compliance percent among 
the VIN and CON group was 92.7 ±13.3% (n=18) and 89.1 ±18.9% (n=20) respectively. 
Seven participants lost their compliance calendar, 4 of those participants were in the 
CON group and 3 from the VIN group.  Compliance to vinegar supplementation among 
all reporting participants ranged from 19.6-100%. 
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Eight-week variances between the VIN and CON groups are shown in Table 2.  
Pre and post data were analyzed for time and interaction effects.  General linear model 
univariate analysis was used to determine significance for the 8-week change between 
groups.  Age, gender, baseline BMI, and change in physical activity (measured in 
metabolic equivalents or METs) were controlled confounding variables in all analyses 
(Table 2) with the exception of mean METs.  No statistically significant differences were 
seen between groups in anthropometric measurements of weight (P=0.652), BMI 
(P=0.855), and waist circumference (P=0.694) between weeks 1 and 8.  Similarly, DXA 
scan data did not show significant changes between groups in visceral fat (P=0.368) or 
total fat (P=0.918) between weeks 1 and 8.  There was a significant increase in both 
groups in physical activity levels (P=0.032 with a large effect size of 0.102) between 
weeks 1 and 8.  There was no difference, however, between the groups (P=0.916) 
indicating that both groups increased their physical activity levels equally.  
 
Table 1: Baseline Characteristics by Groupa 
 VIN (n=21) CON (n=24) P value 
Age (years) 29.6 ±8.1 30.1 ±7.4 0.882 
Height (cm) 163.3 ±7.0 167.9 ±7.4 0.033 
Weight (kg) 74.3 ±11.5 80.7 ±16.9 (n=23) 0.335 
BMI (kg/m2) 27.8 ±4.0 28.5 ±4.9 (n=23) 0.851 
Waist circumference (in) 36.5 ±3.3 36.9 ±4.0 (n=23) 0.906 
% Compliance 92.7 ±13.3 (n=18) 89.1 ±18.9 (n=20) 0.764 
aData are mean±SD. P value for baseline differences between groups (Mann-Whitney 
nonparametric test). Data considered significant at P<0.05. One outlier removed from 
baseline data (outlier ≥3 SD from mean). 
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Table 2.  Anthropometry: Baseline data, week 8 data, and the 8-week change data, for 
the vinegar (VIN, n=21) and control (CON, n=24) groups a 
  VIN CON P value 
(effect 
size) 
  baseline week 8 change baseline week 8 change 
Age, y 29.6± 8.1     30.1± 7.4       
Gender, M/F 20/1     21/3       
METSb 28.0± 16.8 
36.7± 
34.3 
8.8± 
24.9 
34.2± 28.3 
42.2± 
29.5 
8.0± 
25.6 
0.916 
(0.032) 
Body Mass 
Index, kg/m2 
27.8± 4.0 
27.9± 
3.8 
0.03± 
0.69 
28.5± 4.9 
28.5± 
5.0 
0.08± 
0.49 
0.855 
(0.077) 
Weight, kg 74.3± 11.5 
74.3± 
10.9 
0.01± 
1.79 
80.7± 16.9 
80.9± 
17.2 
0.25± 
1.32 
0.652 
(0.157) 
Waist 
circumferenceb, 
cm 
92.7± 8.4 
91.4± 
9.4 
-1.1± 
3.3 
93.7± 10.2 
92.5± 
10.9 
-1.3 ± 
2.7 
0.694 
(0.085) 
Visceral fat, 
cm3 
672.0± 
469.5 
688.4± 
471.9 
16.4± 
94.1 
569.4± 
547.1 
562.0± 
536.0 
-7.4± 
85.2 
0.368 
(0.266) 
Body fat, % 40.4± 7.2 
40.2± 
7.3 
-0.17± 
0.93 
37.9± 7.4 
37.8± 
7.8 
-0.08± 
1.57 
0.918 
(0.067) 
aData are mean±SD; baseline values do not differ between groups (P>0.05; independent t-
test).  P value for 8-week change between groups (GLM univariate analysis; age, gender, 
baseline body mass, and change in METS were controlled in all analyses with the exception of 
METS).  Effect size is Cohen’s d (0.2=small; 0.5=medium; 0.8=large). bSignificant time 
effect.  
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Figure 2.  A: Comparison of mean visceral fat (cm3) between groups at week 1 and 
week 8 (P=0.368, d=0.266).  B: Comparison of mean waist circumference (in) 
between groups at week 1 and week 8 (P=0.871, d=0.871). Data considered 
significant at P<0.05. VIN: n=21, CON: n=24. 
 
 
 
Figure 3: Comparison of mean body fat (%) between groups at week 1 and 
week 8 (P=0.294, d=0.067). Data considered significant at P<0.05. VIN: 
n=21, CON: n=24. 
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Blood samples were obtained in a fasted state at the beginning and end of the trial. 
Samples from two participants, one in the VIN group and one in the CON group, were 
not collected which explains the smaller sample size in each group.  One participant 
refused to have blood drawn, and the other due to difficulties obtaining the sample.  
There were no outliers found in the blood sample analysis.  
Changes in blood indices between the VIN and CON groups at weeks 1 and 8 are 
shown in Table 3.  General linear model multivariate analysis was used to determine 
significance for the 8-week change between groups, controlling for age, gender, and 
baseline data for BMI, insulin, glucose, HOMA, and change in physical activity (METs) 
in all analyses (Table 3).  The 8-week change in all blood indices showed a statistically 
significant difference between the vinegar and control groups; fasting blood glucose 
(P=0.003, d=0.487), fasting insulin (P<0.001, d=0.618), and HOMA-IR scores (P<0.001, 
d= 0.607).  Further, Cohen’s effect size suggested a moderate to high practical 
significance in all blood indices.  
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Table 3.  Blood Indices: Baseline data, week 8 data, and the 8-week change data, for 
the vinegar (VIN, n=20) and control (CON, n=23) groups a 
  VIN CON P value 
(effect 
size) 
  baseline week 8 change baseline week 8 change 
Fasting 
glucose, 
mmol/L 
5.1±0.3 5.1±0.3 0.03±0.25 5.2±0.5 5.2±0.4 0.02±0.39 
0.003 
(0.487) 
Fasting 
insulin, 
µU/L 
15.1±8.4 14.2±7.0 -0.9±5.1 13.1±5.9 14.3±6.5 1.2±4.4 
<0.001 
(0.618) 
HOMA-
IR 
3.6±2.1 3.3±1.7 -0.3±1.2 3.1±1.5 3.4±1.7 0.3±1.2 
<0.001 
(0.607) 
aData are mean±SD; baseline values do not differ between groups (P>0.05; independent t-
test).  P value for 8-week change between groups (GLM multivariate analysis; age, gender, and 
baseline data for body mass, insulin, glucose, HOMA, and change in METs were controlled in 
all analyses).  Effect size is Cohen’s d (0.2=small; 0.5=medium; 0.8=large). 
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Figure 5: Comparison of mean fasting insulin (µU/mL) between 
groups at week 1 and week 8 (P<0.001, d=0.618). Data considered 
significant at P<0.05. Data represents all participants who 
completed the trial and provided blood samples (n=43). VIN: n=20, 
CON: n=23.  
 
 
 
Figure 6: Comparison of mean HOMA-IR scores between groups 
at week 1 and week 8 (P<0.001, d=0.607). Data considered 
significant at P<0.05. Data represents all participants who 
completed the trial and provided blood samples (n=43). VIN: 
n=20, CON: n=23. HOMA-IR: Homeostatic Model Assessment 
of Insulin Resistance. 
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Twenty-four-hour dietary recall data was obtained from each participant before 
and after the trial to confirm diet was maintained throughout the study period.  There 
were no significant changes in mean energy and macronutrient intake (Table 4).  Mean 
energy intake among the VIN group at week 1 was 1860 ±813 kcals with 50%, 13%, and 
37% of energy from carbohydrates, protein, and fats respectively.  At week 8, the VIN 
group had a mean energy intake of 1947 ±1025 kcals with 47%, 17%, and 37% of energy 
from carbohydrates, protein, and fats.  Mean energy intake among the CON group at 
week 1 was 2089 ±887 kcals with 43%, 17%, and 34% of energy from carbohydrates, 
protein, and fats respectively.  At week 8, the CON group had a mean energy intake of 
2201 ±1220 kcals with 49%, 15%, and 37% of energy from carbohydrates, protein, and 
fats. 
Table 4: Dietary Recall Data Between Week 1 and Week 8a 
  VIN (n=21) CON (n=24) P value Effect 
Size 
Calories (kcal) Week 1 1860 ±813 2089 ±887 0.947 0.000 
Week 8 1947 ±1025 2201 ±1220 
Carbohydrate (g) Week 1 234 ±124 225 ±95 0.259 0.030 
Week 8 227 ±104 270 ±162 
Protein (g) Week 1 62 ±29 90 ±73 0.234 0.033 
Week 8 81 ±85 83 ±46 
Total fat (g) Week 1 77 ±38 78 ±39 0.633 0.005 
Week 8 79 ±50 90 ±63 
Total fiber (g) Week 1 20 ±13 23 ±11 0.639 0.005 
Week 8 19 ±13 21 ±11 
aData are mean±SD. P value for 8-week change between groups (repeated measures ANOVA). 
Data considered significant at P<0.05. Effect sizes >0.140 are considered large. 
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Participant responses to the exit survey were quantified by scoring their responses 
on a 0, 1, 2, 3 scale, with positive responses earning a score of 0 or 1 and negative 
responses earning a score of 2 or 3.  Chi square statistic was used to determine that a 
slight but insignificant association (approaching significance, P=0.059, with moderate 
effect size, Cramer's V= 0.282) was observed: the type of vinegar supplementation 
received was slightly, but insignificantly, associated with the negative or positive side 
effects experienced with a moderate measured effect. 
 
Table 5. Subjective Side Effects from Participant Exit Survey   
  Negative Side 
Effects 
Positive Side 
Effects 
P value1 
(effect size)2 
VIN,  % [n] 52% [11] 48% [10] 0.059 
(0.282) CON, % [n] 25% [6] 75% [18] 
aData are mean%. 1P value determined using Chi square statistic. Data considered significant at 
P<0.05. 2Cramer’s V effect size. 
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CHAPTER 5 
DISCUSSION 
In the present study, we investigated the effect of daily vinegar consumption on 
fat metabolism, specifically visceral fat, and fasting blood glucose and insulin in healthy 
overweight and obese adults.  The findings from this study failed to show any significant 
differences in waist circumference (P=0.694) or visceral fat (P=0.368) between VIN and 
CON groups after 8 weeks of vinegar treatment.   
The great majority of  research demonstrating a link between vinegar ingestion 
and body fat content have been shown in rat samples.  Animal studies have found 
significant reductions of body fat with vinegar consumption, including weight, visceral 
fat, total fat, and blood fat levels.6,8,11  In their rat model, Ok and colleagues6 explored the 
link between acetic acid metabolism and the oxidation of fat.  Rats were fed a high fat 
diet yet experienced reduced body weight and fat, and serum triglycerides with increased 
intakes of vinegar.6  In addition, elevated levels of phosphorylated AMPK were seen as a 
result of the vinegar intake, resulting in lipolysis and hepatic fatty acid oxidation, and 
ultimately providing further support for a possible mechanism to explain the effects 
vinegar may have on obesity.6  However, with the exception of Kondo and colleagues4, 
human studies on vinegar consumption have not shown statistically significant reductions 
in body fat measurements.  A systematic review that compared the effects of treatment 
between animal and human studies reported that there may be limitations to the 
conclusions drawn from animal experiments as they may not translate well to human 
biological systems as previously thought.64  Thus, these findings may provide a rationale 
for the inconsistent conclusions between animal studies showing fat reductions with 
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vinegar treatment and the human studies that show no effect on fat content with vinegar 
treatment.  
In their large scale study of 155 participants, Kondo and colleagues were the first 
to directly study this relationship between vinegar and fat metabolism in humans and 
found significant dose response reductions in mean fat assessments including body 
weight, BMI, body fat ratio (BFR), waist circumference, and serum triglyceride levels.4  
These reductions in fat were seen as early as four weeks and it was on this basis that the 
treatment period for the present study was set at 8 weeks.  However, the results from the 
present study do not agree with their findings.  In their study, a CT scan was used to 
assess body fat changes.  CT scanning is the gold standard in body fat analysis, producing 
highly accurate results.4  Assessment of visceral and total fat in the present study was 
measured using a DXA scanner, which can produce results for body fat content that are 
less accurate than that of CT scans.58  In the Gradmark and colleagues study that found 
DXA measurements to be no more accurate at estimating visceral fat content than 
anthropometric measurements compared to CT scanning, investigators noted that the data 
from previous obesity studies using DXA for assessing body fat may have yielded 
unfavorable conclusions due to poor accuracy of this method.60  Also in the Kondo and 
colleagues study, the body weight variance between measurements (collected at weeks 0, 
4, 8, 12, and post treatment week 16) equated to less than three pounds over a 12-week 
period in all dose vinegar groups which may not realistically translate well to the general 
population in terms of cost-benefit for fat loss.4   
In other vinegar studies that investigated the effects of vinegar consumption, fat 
reduction was not observed in accordance with our findings.  Johnston and colleagues 
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found no significant changes in body weight with a vinegar drink (containing 750mg 
acetic acid) provided twice daily at meals65, nor in body weight or blood lipids66 after a 
12-week vinegar treatment period for both studies.  Further, Lim and colleagues reviewed 
over 20 human intervention trials that examined vinegar consumption and glycemic 
control, and found no significant reductions in body weight or in the lipid profile as a 
result of vinegar consumption.10 
A significant reduction between groups was found in all glycemic blood analyses 
in the present study; fasting blood glucose (P=0.003), fasting insulin (P<0.001), and 
HOMA-IR scores (P<0.001).  This was further substantiated with a moderate to high 
measured effect (Cohen’s d) in all blood indices.  A HOMA-IR score of < 3.0 is 
considered a normal insulin resistance measurement.  The mean HOMA scores for both 
groups at baseline and at week 8 was > 3.0. Participant measures show an overall 
resistance to insulin with normal glucose values.  Considering the inclusion criteria for 
waist circumference in the present study, the above average HOMA scores are indicative 
of the association between large waist size and insulin resistance. 
Attenuated postprandial glucose and insulin blood levels related to regular vinegar 
consumption has been demonstrated in several short-term studies with convincing 
evidence.  A recent meta-analysis concluded that postprandial glucose and insulin 
response may be reduced with regular ingestion of vinegar, and the overall effect size 
was stronger in subjects with impaired glucose tolerance, insulin resistance, and diabetes 
when compared to healthy subjects without metabolic disorders.25  However, longer term 
trials are needed to determine safe, continuous consumption of vinegar as a means to 
promote glycemic control in various metabolic disorders.  
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All participants who completed this study reported their experience with any 
symptoms, positive or negative, they may have had at any point over the 8-week trial 
related to their vinegar supplementation (Appendix F,G).  Participant responses to the 
exit survey were quantified using Chi square statistic.  The type of vinegar 
supplementation received was slightly, but insignificantly, associated with the negative or 
positive side effects experienced.  Based on participant responses overall, the negative 
side effects of the vinegar supplementation were predominately characterized by nausea 
or sickness, and adverse stomach or bowel issues with moderate effect size (Cramer's V= 
0.3); while the positive side effects were predominately characterized by appetite 
suppression, decreased heart burn or acid reflux, or improved overall vitality. 
The primary negative response among VIN group participants involved symptoms 
of nausea or stomach issues after intake of their liquid supplement; while the primary 
positive response was overall decreased appetite throughout the day and feeling of weight 
loss.  Single negative responses by individuals in the VIN group include: burning of 
esophagus or stomach, frequent bowel movements (first day only), vinegar-smelling 
sweat, feeling of eroded front teeth, or reflux if taken too late.  One participant 
experienced diarrhea after ingestion and reduced daily liquid vinegar supplementation by 
half.  Single responses to “positive symptoms” among VIN group participants include: 
improved or increased bowel movements, reduced stomach bloating, increased water 
consumption, and feeling better overall. 
CON group participants had individual responses to “negative symptoms” that 
were unspecific or isolated occurrences with no common complaints between group 
participants.  Single negative responses by CON group participants include: stomach pain 
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or bloating, sometimes mild nausea, or tired eyes right after ingestion, and stomach ache 
if taken too early or late in the day.  The majority of CON group participants indicated 
more positive responses to their supplement compared to the VIN group.  The primary 
positive response among the group involved the feeling of weight loss or feeling leaner 
with pill intake, and some experienced improved digestion, or decreased symptoms of 
acid reflux or heart burn.  Other single responses to “positive symptoms” by the CON 
group include decreased appetite, and improved digestion.   
As noted, some participants experienced a decrease in heart burn or acid reflux 
symptoms. This may be explained by preliminary research proposing that acid ingestion 
may alleviate heart burn symptoms related to gastroesophageal reflux disease (GERD).  
A crossover pilot study (unpublished) examined the efficacy of vinegar on reducing 
heartburn symptoms that were related to GERD.67  GERD occurs when the lower 
esophageal sphincter (LES) is weakened, which ultimately allows for the acidic contents 
of the stomach to flow back up into the esophagus.67  Severity of this condition is 
dependent on how weak the LES is and the effect of saliva to buffer bolus acidity.67  
Saliva secretion increases when acidic foods and beverages are ingested, buffering the 
acidity as the bolus makes its way down the GI tract via primary peristalsis initiated by 
swallowing muscle movements.67  Secondary peristaltic waves can be triggered by stretch 
receptors in the esophageal lining as well as pH receptors.67  The proposed mechanism to 
which this pilot study was designed was based on the acid sensitive receptors in the 
esophageal mucosa that are triggered when the intraluminal pH drops.  Stimulation of 
these receptors induces esophageal peristaltic muscle contractions, propelling a food 
bolus down the esophagus into the stomach.67  Additionally, the acidity of vinegar may 
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also reduce the symptoms of heart burn related to GERD by amplifying the primary 
peristalsis movements and stretching out its duration.67   
Vinegar has received substantial marketing attention as a result of reports that 
vinegar influences appetite suppression, lending to its popularity as a weight loss 
supplement.22  Subjective reports from several participants in this study also agree with 
the appetite suppression side effects of vinegar.  In a previously discussed study, Darzi 
and colleagues22 investigated the palatability and tolerability of vinegar and their 
influence on appetite, both physiologically and gustatorily (taste sensation).  They found 
that appetite was influenced by the palatability of vinegar and by subsequent feelings of 
nausea.22  Inasmuch as palatability decreased (becoming less pleasurable), nausea 
increased resulting in reduced appetite, prolonged fullness, and a reduction in subsequent 
energy intake.22  Based on these findings (appetite suppression and nausea related to the 
liquid vinegar ingestion) and the self-reported side effects from the VIN group in the 
present study, it would be expected that energy intake (as determined from the 24-hour 
dietary recalls) over the trial period would have decreased.  However, data from dietary 
recalls obtained before and after the trial were not significantly different in the VIN group 
between weeks 1 and 8.  Mean energy intakes were fairly consistent, despite several 
reports of suppressed appetite or induced nausea.  Each participant received a calendar to 
track their vinegar supplementation each day.  The mean compliance percent among the 
VIN group was 92.7 ±13.3% (n=18; 3 lost their compliance calendars), therefore it is 
unlikely that a lack of compliance to the liquid vinegar supplement would have explained 
the inconsistency between the unchanged pre and post energy intakes and self-reported 
side effects of liquid vinegar ingestion that included nausea or appetite suppression.  
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Participants were instructed to maintain their dietary intakes throughout the trial period.  
It is possible that participants strictly followed study protocols despite vinegar-induced 
appetite cues to suppress hunger.   
It is also interesting to note that among the VIN group there was a slight reduction 
in carbohydrate intake, -3%, and a slight increase in protein intake, +4%.  In contrast, the 
CON group had a 6% increased intake of carbohydrates and a 3% increase in fat intake.  
A finding from the Darzi and colleagues study suggests that vinegar may have influence 
on curbing sweet cravings (which are primarily satisfied by carbohydrates) however, this 
was shown with a trend approaching significance (P=0.058) among treatment groups.22  
The present study examined the relationship between vinegar and visceral fat, therefore it 
was not in the nature of the study design to place more specific controls to fully assess 
dietary intake.  It may be worthwhile for future research to study the impact of daily 
vinegar ingestion on appetite, macronutrient composition of meals, and on respiratory 
quotient (RQ) variances. 
This study had several limitations.  The use of DXA scanning to assess body fat 
and distribution may generate conclusions based on results that may not be the most 
accurate compared to other methods of fat assessment.  Eight weeks may be too short a 
time span to see a significant change in visceral fat.  Finally, dietary intake was self-
reported via 24-hour recall and may be not reflect true compliance to maintain normal 
dietary habits. 
We conclude that the findings from this study did not support our hypothesis that 
daily red wine vinegar consumption will reduce visceral fat and waist circumference in 
healthy adults with central obesity.  Further research is indicated on the association 
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between vinegar ingestion and appetite suppression, macronutrient distributions within 
the diet, and substrate utilization, as well as the safety of long-term daily vinegar 
consumption.   
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I am a graduate student in the School of Nutrition and Health Promotion at 
Arizona State University and am conducting a research study to examine 
health benefits of vinegar supplementation.  I am inviting your participation 
in the screening process, which will consist of answering questions regarding 
health history, demographics, and scheduling availability. You have the right 
to not answer any question, and to stop participation at any time. 
We are recruiting health adults who have a little extra belly fat. Your 
participation in this survey and study is voluntary. If you choose not to 
participate or to withdraw from the study at any time, there will be no 
penalty.  Your responses to this survey will be confidential.  If you meet the 
criteria for this study, you will be contacted to schedule an in-person 
appointment at the downtown campus of Arizona State University. 
 
If you have any questions concerning the research study, please contact the 
research team at lisa.a.gonzalez@asu.edu. If you have any questions about 
your rights as a subject/participant in this research, or if you feel you have 
been placed at risk, you can contact the Chair of the Human Subjects 
Institutional Review Board, through the ASU Office of Research Integrity and 
Assurance, at (480) 965-6788. 
 
By selecting “I agree” below you are agreeing to continue forward with the 
survey and be contacted by investigators (via e-mail) to schedule an 
appointment, should you qualify. 
1. What is your email? w 
 
2. Are you an ASU student, staff, or faculty on the downtown campus? w 
Yes 
No 
3. How old are you? 
w 
Age (years)  
4. Are you male or female? w 
Male 
Female 
5. Do you smoke cigarettes? w 
Yes 
No 
6. Do you consider yourself to have extra belly fat? w 
Yes 
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No 
Unsure 
7. How tall are you? w 
Height (inches) (Note: 5 feet=60 inches)  
8. How much do you weigh? w 
Weight (pounds)  
9. Are you generally healthy? (e.g., not seeing a doctor for a medical condition) w 
Yes 
No 
10. Do you take a prescription drug daily? (excluding birth control) w 
Yes 
No 
11. Are you willing to drink a diluted vinegar drink daily or consume a vinegar pill 
daily for 8 weeks? w 
Yes 
No 
12. Do you have any food allergies or diet restrictions? w 
Yes 
No 
13. Have you lost or gained more than 10 pounds in the last six months? w 
Yes 
No 
Unsure 
14. If female, are you pregnant, or hope to get pregnant, in the next few months? w 
Yes 
No 
15. Are you ok with providing a small blood sample on two occasions during the 
research trial? w 
Yes 
No 
16. Are you willing to meet with investigators at the ABC1 building on the ASU 
Downtown campus on 3 occasions? w 
Yes 
No 
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The Impact of Vinegar on Fat Metabolism and Blood Values 
INTRODUCTON 
The purposes of this form are (1) to provide you with information that may affect your decision  
as to whether or not to participate in this research study, and (2) to record your consent if  
you choose to be involved in this study. 
RESEARCHERS 
Dr. Carol Johnston, a Nutrition professor, and Lisa Gonzalez, a graduate student, at Arizona  
State University Downtown, Phoenix, have requested your participation in a research study. 
STUDY PURPOSE 
The purpose of this 8-week long research study is to evaluate the impact of vinegar ingestion  
on fat metabolism and blood glucose concentrations.   
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are 18-45 years of age and healthy. If female, you are not currently 
pregnant or planning a pregnancy. Also, you have not had abdominal surgery or chronic conditions 
involving your digestive track. This study will involve the completion of a brief health history  
questionnaire to demonstrate the absence of other conditions that may contraindicate participation.  
 
This research entails that you visit our test facilities on three occasions on ASU’s Downtown Phoenix 
campus. At your first visit (lasting ~30 minutes) you will complete a health history questionnaire and          
a 24-h diet recall to confirm your eligibility. Your height, weight, and waist circumference will be 
measured.  You will be scheduled for the second visit which is the start of the 8-week study.  You will   
need to fast for this visit (no food or drink with the exception of water for >8 hours).  A blood sample       
will be taken from an arm vein (~2 tablespoons), and the DXA scan will take place.  For the DXA scan 
(performed using an FDA‐approved Dual‐energy X‐ray Absorptiometry machine) you will be asked to      
lie face up on an open, padded table for 7 minutes while the scanner arm of the DXA machine passes      
over the entire body. You can wear regular clothing but any metal (clothing or accessory) must be     
removed. You will be exposed to a small amount of radiation (1‐4 microSieverts) that is within an 
acceptable range per the FDA. For comparison, you would be exposed to approximately 80      
microSieverts on a transatlantic airline flight of 8 hours, 50 microSieverts living in Denver, Colorado,        
at an elevation of 5,000 feet for approximately 4 weeks, or 30 to 40 microSieverts during a typical chest      
x‐ray. (For test accuracy, you will be asked about test procedures using barium/isotopes in the recent       
past and be scheduled for your visit with an adequate lapse of time.)  At this visit you will also receive    
your vinegar supplement which is to be consumed daily as instructed.  This visit is expected to last   ~1 
hour.  The third visit will mirror visit 2, and you will receive a $10 gift card.   
RISKS 
Mild discomfort due to the venous blood draw may occur.  Blood sampling may be 
associated   with nausea, dizziness, faintness, and bruising at the site of needle insertion.   
A trained phlebotomist will collect the blood and manage participant reaction as  
appropriate.  Regarding the DXA scan, anytime you are exposed to radiation there  
is potential risk. Females will take a urine pregnancy test prior to the DXA scan to  
demonstrate the absence of a pregnancy. A certified X‐ray technician will complete all DXA  
scans.  
BENEFITS  
You may not benefit from this study, but once the study is complete you will be provided with  
your test results if desired including bone mineral density and body fat composition. 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably change your decision 
 about participating, then they will provide this information to you.      
CONFIDENTIALITY 
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 All information obtained in this study is strictly confidential unless disclosure is required by  
law. The results of this research study may be used in reports, presentations, and  
publications, but your name or identity will not be revealed.  In order to maintain confidentiality  
of your records, Dr. Johnston will use subject codes on all data collected, maintain a master 
 list separate and secure from all data collected, and limit access to all confidential information  
to the study investigators.   
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or prejudice  
toward you.  Your decision will not affect you any manner. 
COSTS AND PAYMENTS 
You will receive a $10 gift card at the completion of data collection. 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your legal  
rights. However, in the event of harm, injury, or illness arising from this study, neither  
Arizona State University nor the researchers are able to give you any money,  
insurance coverage, free medical care, or any compensation for such injury.  Major injury is  
not likely but if necessary, a call to 911 will be placed.  
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study,  
before or after your consent, will be answered by Dr. Carol Johnston, 500 N. 3rd St.,  
Phoenix, AZ 85004. [602-827-2265]  
 
If you have questions about your rights as a subject/participant in this research, or if you feel  
you have been placed at risk, you can contact the Chair of the Human Subjects  
Institutional Review Board, through the ASU Research Compliance Office, at 480-965 6788.   
 
This form explains the nature, demands, benefits and any risk of the project.  By signing this form you 
agree knowingly to assume any risks involved.  Remember, your participation is voluntary.  You may 
choose not to participate or to withdraw your consent and discontinue participation at any time without 
penalty or loss of benefit.  In signing this consent form, you are not waiving any legal claims, rights, or 
remedies.  A copy of this consent form will be given to you.   
 
Your signature below indicates that you consent to participate in the above study.   
______________________________      ______________________________  ______ 
Subject's Signature             Printed Name         Date 
____________________________   ________________________________      
Contact phone number                     Email    
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the  
potential benefits, and possible risks associated with participation in this research  
study, have answered any questions that have been raised, and have  
witnessed the above signature. These elements of Informed Consent conform to the 
Assurance given by Arizona State University to the Office for Human Research Protections  
to protect the rights of human subjects. I have provided the subject/participant a copy of  
this signed consent document." 
 
 
Signature of Investigator____________________________________        Date___________ 
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HEALTH HISTORY QUESTIONNAIRE                                ID#___________________ 
1. Gender:  M    F 
 
2. Age:  __________ 
 
3. Have you lost or gained more than 10 lbs in the last 12 months?         Yes         No 
     If yes, how much lost or gained? _________     How long ago? ___________ 
 
4. Ethnicity: (please circle one)  Native American     African-American     Caucasian     
Hispanic     Asian     Other 
 
5. Education (please circle)   High school diploma     AA/vocational degree     College degree    MS 
degree     PhD degree 
 
6. Do you smoke?  No, never ________   
        Yes _______     # Cigarettes per day = ________                               
                               I used to, but I quit _______ months/years (circle) ago 
 
7. Women only:  Have you ever been pregnant? ___________________ 
                             If yes, date of last pregnancy? ___________ 
              Are you pregnant now or plan a pregnancy in the next 3 months?       Yes           
No 
 
8.  Do you take any medications regularly?     Yes No           If yes, list type and 
frequency: 
     
Medication    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________’ 
 
 
9. Do you currently take supplements (vitamins, minerals, herbs, etc.) ?    Yes    No         
If yes, list type and frequency:                               
     
Supplement    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________ 
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10.  Please check (YES/NO) if you currently have or if you have ever been clinically 
diagnosed with any of the following  diseases or symptoms: 
 
 
 YES NO  YES NO 
Coronary Heart Disease   Chest Pain   
High Blood Pressure   Shortness of Breath   
Heart Murmur   Heart Palpitations   
Rheumatic Fever   Any Heart Problems   
Irregular Heart Beat   Coughing of Blood   
Varicose Veins   Feeling Faint or Dizzy   
Stroke   Lung Disease   
Diabetes   Liver Disease   
Low Blood Sugar   Kidney Disease   
Bronchial Asthma   Thyroid Disease   
Hay Fever   Anemia   
Leg or Ankle Swelling   Hormone Imbalances   
Eating Disorder   Depression   
              
 
 
 
11.  Have you ever had abdominal surgery?    Yes      No 
 
12.  Do you have any of the conditions listed below?      Yes         No                                    
             acid reflux, ascites, pancreatitis, diverticulitis/diverticulosis, Crohn’s disease, 
and/or irritable bowel syndrome 
13.  Please circle the number of times you did the following kinds of exercises for more 
than 15 minutes last week. 
Mild exercise (minimal effort):   
Easy walking, golf, gardening, bowling, yoga, fishing, horseshoes, 
archery, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
  
Moderate exercise (not exhausting):   
Fast walking, easy bicycling, tennis, easy swimming, badminton, 
dancing, volleyball, baseball, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
Strenuous exercise activities (heart beats rapidly):   
Running, jogging, hockey, football, soccer, squash, basketball, cross 
country skiing, judo, roller skating, vigorous swimming, vigorous 
long distance bicycling, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
 
14. Are you healthy and fit?              Yes        No           
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             Comments:    
__________________________________________________________________
______ 
15.  How much alcohol do you drink? (average  #drinks  per week)  ___________ 
 
16.  Do you have any food allergies?      Yes    No    
       If yes, explain: 
________________________________________________________________________
______ 
 
17. Do you follow a special diet?        Yes      No 
       If yes, explain:  
________________________________________________________________________
______ 
 
18.  Do you plan to change your diet in the next 8 weeks?      Yes     No 
       If yes, explain:  
________________________________________________________________________
______ 
 
19.  Do you plan to change your exercise level in the next 8 weeks?      Yes     No 
        If yes, explain:  
____________________________________________________________________
______ 
 
20.  Are you willing to consume vinegar supplements daily for 8 weeks?      Yes       No 
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Exit Survey Responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symptoms VIN 
Freq. 
CON 
Freq. 
Total % 
Nausea or sick after intake 
*(sometimes)  
8 *1  9 20 
Decreased appetite 4 1 5 11 
Overall: felt better, leaner 1 4 5 11 
During ingestion: burning esophagus or stomach 
burned/ grumbled  
4  4 9 
Shortly after ingestion: stomach pain/bloating 3 1 4 9 
Improved digestion/bloating 
* (improved acid reflux/heart burn) 
1 *3 4 9 
Improved bowel movements  2  2 4 
Diarrhea or increased frequency of bowel 
movements ≥ 1 day 
2  2 4 
Improved dietary habits as a result of vinegar 
supplement  
2  2 4 
Weight loss 2  2 4 
Reflux if taken too late at night 1  1 2 
Front teeth felt eroded 1  1 2 
Sweat smelled like vinegar 1  1 2 
Didn’t notice any changes 1  1 2 
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Symptoms: Break Down by Group 
 
Positive Symptoms CON: Freq. Negative Symptoms CON: Freq. 
Felt loss of weight or more 
lean 
*1 subject “ Felt as if I lost 
weight while still eating the 
same” 
3 Stomach ache if taken too 
early/late 
1 
Decreased appetite 1 Sometimes experienced nausea 1 
Decreased symptoms of acid 
reflux 
1 “Eyes felt tired after taking it” 1 
Reduced heart burn 1   
Overall, felt better 1   
Improved digestion 1   
 
 
 
 
 
 
Positive Symptoms VIN: Freq. Negative Symptoms VIN: Freq. 
Decreased appetite 4 Nausea 5 
Weight loss 
*1 subject “more room in 
clothes” 
2 Sick 
*1 subject “Very sick, had to cut 
down to once per day in evening 
before big meal” 
3 
Increase in bowel 
movements 
1 Experienced stomach pain right 
after intake of supplement; lasted 
~20 minutes each time 
2 
Easier to defecate 1 Stomach burned or grumbling 
after intake 
2 
Stomach was not bloated as 
usual 
1 Burning esophagus 2 
Increased overall daily water 
consumption   
1 Bad taste 1 
Became more conscious of 
what was being consumed 
1 Frequent bowel movements the 
first day 
1 
Body felt better, more 
refreshed overall 
1 Stomach bloated 1 
  Diarrhea 1 
  Reflux if taken too late at night 1 
  Front teeth felt eroded 1 
  Sweat smelled like vinegar 1 
  Didn’t notice any changes 1 
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Did you have problems consuming supplement daily during study: 
 Never Occasionally Weekly Daily 
VIN 10 5 2 4 
CON 17 5 0 0 
 
Did you like taking supplement: 
 Frequency 
No (terrible taste) VIN: 8 
CON: 0 
Not really (it was hard to remember to 
take the supplement) 
VIN: 2 
CON: 3 
Neutral (I did it since I was in this study 
and said I would) 
VIN: 9 
CON: 3 
Yes (the supplement was easy to take) VIN: 3 
CON: 16 
Yes (great taste) VIN: 2 
CON: 1 
 
Comments on problems consuming supplement daily: 
Hard to take with you if you have to go somewhere 
Hard to fit into a busy day 
Hard to remember to take each day 
Timing is often a problem 
Hard to fit into schedule  
Felt sick after taking it 
Tasted bad, had to psyche self into taking it 
Burned going down 
 
 
